167 related articles for article (PubMed ID: 37417162)
1. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: A review.
Kelleci K; Allahverdiyev A; Bağirova M; Ihlamur M; Abamor EŞ
J Vector Borne Dis; 2023; 60(2):125-141. PubMed ID: 37417162
[TBL] [Abstract][Full Text] [Related]
2. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
Dinc R
Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
[TBL] [Abstract][Full Text] [Related]
3. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
4. Development of nano-carriers for
Askarizadeh A; Badiee A; Khamesipour A
Expert Opin Drug Deliv; 2020 Feb; 17(2):167-187. PubMed ID: 31914821
[No Abstract] [Full Text] [Related]
5. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
Ratnapriya S; Keerti ; Sahasrabuddhe AA; Dube A
Vaccine; 2019 Jun; 37(27):3505-3519. PubMed ID: 31103364
[TBL] [Abstract][Full Text] [Related]
6. Vaccine candidates for leishmaniasis: a review.
Nagill R; Kaur S
Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
[TBL] [Abstract][Full Text] [Related]
7. Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis.
Coutinho De Oliveira B; Duthie MS; Alves Pereira VR
Hum Vaccin Immunother; 2020 Apr; 16(4):919-930. PubMed ID: 31634036
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
10. Studies on the protective efficacy of freeze thawed promastigote antigen of Leishmania donovani along with various adjuvants against visceral leishmaniasis infection in mice.
Thakur A; Kaur H; Kaur S
Immunobiology; 2015 Sep; 220(9):1031-8. PubMed ID: 26001730
[TBL] [Abstract][Full Text] [Related]
11. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
12. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant effects of TLR agonist gardiquimod admixed with Leishmania vaccine in mice model of visceral leishmaniasis.
Goyal DK; Keshav P; Kaur S
Infect Genet Evol; 2021 Sep; 93():104947. PubMed ID: 34052416
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Vaccines Against Leishmania Based on Patent Applications.
Thomaz-Soccol V; Ferreira da Costa ES; Karp SG; Junior Letti LA; Soccol FT; Soccol CR
Recent Pat Biotechnol; 2018; 12(1):21-32. PubMed ID: 28494723
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
17. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice.
Peters NC; Bertholet S; Lawyer PG; Charmoy M; Romano A; Ribeiro-Gomes FL; Stamper LW; Sacks DL
J Immunol; 2012 Nov; 189(10):4832-41. PubMed ID: 23045616
[TBL] [Abstract][Full Text] [Related]
19. Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis.
Lage DP; Machado AS; Freitas CS; Vale DL; Linhares FP; Cardoso JMO; Oliveira-da-Silva JA; Ramos FF; Pereira IAG; Ludolf F; Tavares GSV; Bandeira RS; Oliveira JS; Menezes-Souza D; Duarte MC; Galdino AS; Christodoulides M; Chávez-Fumagalli MA; Roatt BM; Martins VT; Coelho EAF
Mol Immunol; 2023 Mar; 155():79-90. PubMed ID: 36731193
[TBL] [Abstract][Full Text] [Related]
20. Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs.
Kaye PM; Cruz I; Picado A; Van Bocxlaer K; Croft SL
Semin Immunopathol; 2020 Jun; 42(3):247-264. PubMed ID: 32152715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
